What the FDA labels say about taking them together
Insulin glulisine and pentoxifylline
Insulin glulisine's FDA label of November 25, 2025 names pentoxifylline in its drug interactions section; the pentoxifylline label PlainMeds reads does not name insulin glulisine. The insulin glulisine label: “… agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. …”
Check it at the source: the insulin glulisine FDA label on DailyMed (effective November 25, 2025); the pentoxifylline FDA label on DailyMed (effective May 15, 2026, Rising Pharma Holdings, Inc.).
What does the insulin glulisine label say about pentoxifylline?
Insulin glulisine label, drug interactionsDrugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.
Source: FDA drug label (Apidra), sanofi-aventis U.S. LLC, effective November 25, 2025 (SPL set e7af6a7a-8046-4fb4-9979-4ec4230b23aa), via openFDA; the full label on DailyMed
What does the pentoxifylline label say about insulin glulisine?
Pentoxifylline's label (effective May 15, 2026) does not name insulin glulisine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pentoxifylline), Rising Pharma Holdings, Inc., effective May 15, 2026 (SPL set cd840a2c-2a0e-4b2b-84ff-a0406bb6fa37), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin glulisine | Pentoxifylline | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $8.16 per mL 100 unit/mL vial | $0.227 per tablet 400 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once